
Chemical Structure
Ritonavir [155213-67-5]

AG-CR1-3683
Overview
- SupplierAdipoGen Life Sciences
- Product NameRitonavir
- Delivery Days Customer10
- CAS Number155213-67-5
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationWarning
- Molecular FormulaC37H48N6O5S2
- Molecular Weight720.9
- Scientific DescriptionChemical. CAS: 155213-67-5. Formula: C37H48N6O5S2. MW: 720.9. . HIV-1 and HIV-2 protease inhibitor. Glucose transporter 1 (GLUT1) and 4 (GLUT4) inhibitor. Inhibits transport of glucose across the plasma membranes of mammalian cells and consequently decreases glycolysis. Useful agent for immunometabolism research. Antitumor agent. Apoptosis inducer and cell proliferation inhibitor in GLUT1/GLUT4 overexpressed cancer cell lines. Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Among the fourteen SLC2A family members, GLUTs 1 and 4 are high-affinity glucose transporters. - HIV-1 and HIV-2 protease inhibitor. Glucose transporter 1 (GLUT1) and 4 (GLUT4) inhibitor. Inhibits transport of glucose across the plasma membranes of mammalian cells and consequently decreases glycolysis. Useful agent for immunometabolism research. Antitumor agent. Apoptosis inducer and cell proliferation inhibitor in GLUT1/GLUT4 overexpressed cancer cell lines. Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Among the fourteen SLC2A family members, GLUTs 1 and 4 are high-affinity glucose transporters. Inhibits 20S proteasome chymotrypsin-like activity. The proteinase inhibitor Kaletra, which is a mixture of the HIV-1 proteinase inhibitors lopinavir and ritonavir has been shown to be effective against SARS-CoV and MERS-CoV. Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the coronavirus endopeptidase C30 (CEP_C30) of SARS-CoV-2. An initial randomized trial study was not successful.
- SMILESCC(C1=NC(CN(C(N[C@H](C(N[C@H](C[C@@H]([C@@H](NC(OCC2=CN=CS2)=O)CC3=CC=CC=C3)O)CC4=CC=CC=C4)=O)C(C)C)=O)C)=CS1)C
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200